FIGURE 3.

Nanoparticle adjuvants in the clinic. (a) Make‐up of unique vaccine formulations containing nanoparticle adjuvants in the clinical trial space separated by nanoparticle type: lipid nanoparticles, Matrix‐M, betulin nanoparticle (NP), gold nanoparticle (GNP), nanostructured lipid carriers (NLC), and lipid inorganic nanoparticles (LION). The number of unique vaccine formulations as well as the resulting percent of the whole space is provided. (b) The number of clinical trials that contain a lipid nanoparticle by responsible party of the clinical trial. This is defined by both number of trials with unique vaccine formulations and number of trials with repeat formulations.